Nano-antibody and its application based on SARS-CoV-2 S protein
US11820811B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 9, 2021 |
| Grant date | Nov 21, 2023 |
| Priority date | — |
| Expiry date | Feb 2, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2469/10
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A nanobody and its application based on SARS-CoV-2 S protein are provided, and the present disclosure relates to biomedical technology. The present disclosure chooses the Spike S1+S2 ECD of SARS-CoV-2 as a target, and screens the nanobody against of SARS-CoV-2 by using a nanobody library. After an ELISA test, the Spike S1+S2 ECD target of SARS-CoV-2 can be specifically identified while a SPIKE RBD target is identified, and a binding signal is relatively strong. The corresponding nanobody sequence is constructed into a prokaryotic expression vector for expression and purification to express the target nanobody successfully. After the purification, the purity is greater than 90%. The ELISA test of VHH nanobody showed that the purified nanobody has higher affinity to the two targets.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.